Shannon Renee Marshall
Nail Technician at Royston Ave, Baltimore, MD
License number
Colorado 365556
Issued Date
Jan 9, 1997
Renew Date
Apr 1, 2016
Expiration Date
Mar 31, 2018
Type
Nail Technician
Address
Address
3009 Royston Ave, Baltimore, MD 21214
Professional information
Shannon Marshall
Location:
Baltimore, Maryland Area
Industry:
Defense & Space
Skills:
VHDL, Embedded Systems, FPGA, C, C++, Linux, Java, Systems Engineering, Electrical Engineering, RF, PCB design, Visual Basic, Debugging, Spectrum Analyzer
B7-H4 Fusion Proteins And Methods Of Use Thereof
US Patent:
2012027, Nov 1, 2012
Filed:
Aug 31, 2010
Appl. No.:
13/392811
Inventors:
Solomon Langermann - Baltimore MD, US
Linda Liu - Clarksville MD, US
Joseph R. Podojil - Downers Grove IL, US
Stephen D. Miller - Oak Park IL, US
Shannon Marshall - Baltimore MD, US
Linda Liu - Clarksville MD, US
Joseph R. Podojil - Downers Grove IL, US
Stephen D. Miller - Oak Park IL, US
Shannon Marshall - Baltimore MD, US
International Classification:
A61K 39/395, A61P 29/00, C07K 19/00
US Classification:
4241341, 5303873
Abstract:
Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
Fgfr Extracellular Domain Acidic Region Muteins
US Patent:
8338569, Dec 25, 2012
Filed:
Aug 4, 2009
Appl. No.:
12/535479
Inventors:
Shannon Marshall - Baltimore MD, US
Deborah H. Charych - Albany CA, US
Ali Sadra - San Mateo CA, US
Deborah H. Charych - Albany CA, US
Ali Sadra - San Mateo CA, US
Assignee:
Five Prime Therapeutics, Inc. - South San Francisco CA
International Classification:
C07K 14/50, C07K 14/705, C07H 21/04
US Classification:
530351, 530350, 4241841, 514 76, 536 231, 536 234
Abstract:
Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.
Methods Of And Compositions For Stimulation Of Glucose Uptake Into Muscle Cells And Treatment Of Diseases
US Patent:
2011031, Dec 29, 2011
Filed:
Nov 29, 2010
Appl. No.:
12/955779
Inventors:
Junyu Lin - Palo Alto CA, US
Srinivas Kothakota - Pacifica CA, US
Ge Wu - La Canada CA, US
Stephen Doberstein - San Francisco CA, US
Thomas Brennan - San Jose CA, US
Lorianne Masuoka - Oakland CA, US
Minmin Qin - Pleasanton CA, US
Shannon Marshall - Baltimore MD, US
Yan Wang - Redwood City CA, US
Diane Hollenbaugh - Mountain View CA, US
Lewis T. Williams - Mill Valley CA, US
Srinivas Kothakota - Pacifica CA, US
Ge Wu - La Canada CA, US
Stephen Doberstein - San Francisco CA, US
Thomas Brennan - San Jose CA, US
Lorianne Masuoka - Oakland CA, US
Minmin Qin - Pleasanton CA, US
Shannon Marshall - Baltimore MD, US
Yan Wang - Redwood City CA, US
Diane Hollenbaugh - Mountain View CA, US
Lewis T. Williams - Mill Valley CA, US
International Classification:
A61K 38/18, A61P 3/10, A61K 38/28
US Classification:
514 65, 514 68
Abstract:
The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.
Compositions For Treating Arthritis Comprising Hg1023575 Polypeptide
US Patent:
8324165, Dec 4, 2012
Filed:
May 13, 2009
Appl. No.:
12/992582
Inventors:
Kalyani Penta - Palo Alto CA, US
Srinivas Kothakota - Pacifica CA, US
Lewis T. Williams - Mill Valley CA, US
Kevin Hestir - Kensington CA, US
Shannon Marshall - Baltimore MD, US
Jeffrey Finer - Foster City CA, US
Yan Wang - Redwood City CA, US
Srinivas Kothakota - Pacifica CA, US
Lewis T. Williams - Mill Valley CA, US
Kevin Hestir - Kensington CA, US
Shannon Marshall - Baltimore MD, US
Jeffrey Finer - Foster City CA, US
Yan Wang - Redwood City CA, US
Assignee:
Five Prime Therapeutics, Inc. - South San Francisco CA
International Classification:
A61P 19/02, A61K 38/17
US Classification:
514 168, 514825, 530350
Abstract:
The invention provides pharmaceutical polypeptide compositions that promote proteoglycan synthesis, and promote the activity of chondrocyte cells, thereby treating arthritis. Methods of providing these compositions to treat arthritis are also provided.
Fgfr Extracellular Domain Acidic Region Muteins
US Patent:
2013000, Jan 3, 2013
Filed:
Sep 12, 2012
Appl. No.:
13/612044
Inventors:
Shannon Marshall - Baltimore MD, US
Deborah H. Charych - Albany CA, US
Ali Sadra - San Mateo CA, US
Deborah H. Charych - Albany CA, US
Ali Sadra - San Mateo CA, US
Assignee:
FIVE PRIME THERAPEUTIC INC. - South San Francisco CA
International Classification:
A61K 39/395, A61P 35/00, A61K 38/02, C07K 2/00, C07K 19/00
US Classification:
4241341, 530300, 5303873, 530362, 514 91
Abstract:
Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.
Antibodies And Other Molecules That Bind B7-H1 And Pd-1
US Patent:
2014004, Feb 13, 2014
Filed:
Apr 19, 2012
Appl. No.:
14/111402
Inventors:
Solomon Langermann - Baltimore MD, US
Linda Liu - Clarksville MD, US
Shannon Marshall - Baltimore MD, US
Sheng Yao - Columbia MD, US
Linda Liu - Clarksville MD, US
Shannon Marshall - Baltimore MD, US
Sheng Yao - Columbia MD, US
Assignee:
AMPLIMMUNE, INC. - Gaithersburg MD
International Classification:
C07K 16/28, G01N 33/68, A61K 39/395
US Classification:
4241721, 5303898, 5303873, 5303913, 435188, 5303917, 435 721, 435 5
Abstract:
The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases.